DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 7.46

Change

-0.20 (-2.61)%

Market Cap

USD 0.17B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

-0.04 (-0.04%)

USD 18.39B
IVV:AU iShares Core S&P 500 AUD

-2.32 (-4.15%)

USD 11.33B
VGS:AU Vanguard MSCI International Sh..

-4.08 (-3.20%)

USD 10.39B
QUAL:AU VanEck Vectors MSCI World ex A..

-1.68 (-3.15%)

USD 7.35B
IOZ:AU Ishares Core S&P/Asx 200

-0.01 (-0.03%)

USD 6.40B
VTS:AU Vanguard US Total Market Share..

-16.89 (-4.11%)

USD 5.71B
STW:AU SPDR® S&P/ASX 200 Fund

-0.03 (-0.04%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

-1.94 (-4.48%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

-1.03 (-2.77%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.03 (+0.02%)

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.09% 46% F 55% F
Dividend Return 0.35% 10% F 6% D-
Total Return -4.74% 43% F 53% F
Trailing 12 Months  
Capital Gain -9.47% 10% F 48% F
Dividend Return 3.04% 42% F 35% F
Total Return -6.43% 11% F 49% F
Trailing 5 Years  
Capital Gain 15.12% 34% F 55% F
Dividend Return 11.29% 24% F 20% F
Total Return 26.42% 29% F 52% F
Average Annual (5 Year Horizon)  
Capital Gain 5.89% 61% D- 55% F
Dividend Return 7.75% 61% D- 55% F
Total Return 1.86% 55% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 8.24% 66% D+ 92% A
Risk Adjusted Return 94.13% 86% B+ 94% A
Market Capitalization 0.17B 32% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.